prof. dr. M.J.M. (Marc ) Bonten

prof. dr. M.J.M. (Marc ) Bonten

Full Professor
prof. dr. M.J.M. (Marc ) Bonten
  • Department of Epidemiology
  • Julius Center Research Program Infectious Diseases

Research Programs

Infection & Immunity



Marc Bonten earned his MD (1991) and PhD (“the role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia, 1994) at the Maastricht University Medical School, the Netherlands. He registered as internist in 2000, as infectious disease specialist in 2002 and as clinical microbiologist in 2008, all at the University Medical Center Utrecht, the Netherlands. From 2008 till March 2021 he was head of the Department of Medical Microbiology. Since 2003 he is head of the research group of Infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care and professor of molecular epidemiology of infectious diseases. He has been a principal investigator in many large scale epidemiologic studies and investigator-initiated randomized trials of prevention and treatment of infectious diseases. His experience covers the full range of epidemiologic study designs including clinical trials, cohorts, case-control studies and mathematical modelling to study antibiotic resistance and infection prevention. Specific research interests include the epidemiology of antibiotic-resistant bacteria such as VRE, MRSA and MDR Enterobacteriaceae, selective decontamination in intensive care unit patients, prevention of ventilator-associated pneumonia, treatment of community-acquired pneumonia, and prevention and treatment of community-acquired pneumonia, including COVID-19.

He is scientific Director of the research theme "Tackling Antimicrobial Resistance" of the Netherlands Centre for One Health (NCOH; (2016-)

He is chairman of the strategic research program Infection & Immunity at the UMC Utrecht. (2017-)

Coordinator of the H2020-funded project ECRAID-Base (March 2021-)

Member of the Koninklijke Nederlandse Academie voor Wetenschappen en Kunsten (Royal Academy of Sciences and Art) (April 2021-)

Side Activities

He acts as paid consultant for Janssen Vaccines (chair of international study steering committee; payments to UMC Utrecht) (2017-), Merck Sharp & Dohme B.V. (advisory board; payments to UMC Utrecht) (2020-),  Pfizer (advisory board; payments to UMC Utrecht) (2021-) and AstraZeneca (advisory board; payments to UMC Utrecht (2021).

He has received speakers fee from Takeda (Nov 2019).

He is a member of the expert panel of Netherlands Veterinary Medicines Institute (SDa) (2019-).

He is a member of the cluster Infectieziektenbestrijding from ZorgOnderzoek Nederland (2019-). 

He is a member of the Scientific Advisory Board of GARDP (Global Antibiotic Research & Development Platform, 2020-).

He is a member of the Independent Data Monitoring Committee of the PSK008 and PSK009 studies on pneumococcal conjugate vaccines from Sanofi Pasteur (2019-). 

He is a member of the Advisory Panel Innovative Treatments COVID-19 of the Ministry of Health, Welfare and Sport (2020-).

Since March 2020 he is a member of the national Outbreak Management Team for COVID-19. 

UMC Utrecht coordinates in the Netherlands the HERALD study; A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older een fase2/3 studie. Bonten is principal investigator for the Netherlands. (2020-)

UMC Utrecht executes the EMPATHY study; a randomized double-blind placebo-controlled multivcenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. Bonten is principal investigator. (2021-)

UMC Utrecht executed the CAPiTA study and 3 related observational studies with PCV13 (2007-2014). Bonten performed until 2016 - on request of Pfizer - presentations on the results of these studies. Payments to UMC Utrecht.

Bonten is, on behalf of UMC Utrecht, coordinator of 4 public-private partnerships funded through the Innovative Medicines Initiative (COMBACTE-NET, CARE, MAGNET en CDI) with the aim to improve efficiency of clinical evaluation of new antimicrobial treatments. Collaboration in this PPP is with AstraZeneca, Pfizer, GSK, Basilea, AiCuris, DaVolterra, Janssen, Sanofi, BioMerieux and MSD ( (2013-) COMBACTE CDI ended in 2021. 

Bonten is, on behalf of UMC Utrecht, co-coordinator of the public-private partnership funded through the Innovative Medicines Initiative (VITAL) in which the effects of aging on vaccine response is investigated. Collaboration in this PPP is with Pfizer, GSK, Janssen, Sanofi, BioMerieux en MSD ( (2017-)

UMC Utrecht is partner in the public-private partnership funded through the Innovative Medicines Initiative (VALUE-Dx) in which the effects of diagnostics in the treatment of respiratory tract infections is investigated. Collaboration in this PPP is with BioMerieux, Abbot, Janssen, BioRad en BD ( Bonten leads the ADEQUATE study in which collaboration is with BioMerieux. (2019-)

UMC Utrecht has collaborated with Atox Bio (2018-2019), Merck (2016-2018), Shionogi (2015), Summit Therapies (2019-2020) and LimmaTech (2021) for which the team led by Bonten selected study sites for clinical studies. 

UMC Utrecht collaborated with Sanofi in a clinical study for influenza vaccination. Bonten was local investigator. (2018-2019).

UMC Utrecht coordinates the PNEUMO studie, funded by Merck; an observational study to quantify the incidence of respiratory tract infections caused by pneumococci in different nEuropean countries. Bonten leads study team. 


Fellowship and Awards

He has been (co-)applicant of a large number of national and international research grants. He is a VICI laureate (2006) from the Dutch Science Association, Principal Investigator of the CAPiTA study, coordinator of the EU-funded project R-GNOSIS, scientific coordinator of the IMI-funded consortiums COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET. He is member of the International Trial Steering Committee of the REMAP-CAP study, and coordinator of ECRAID-Base.  

In 2015 he received the ESCMID 2015 Award for Excellence in Clinical Microbiology and Infectious Diseases.

In 2017 he received a honorary fellowship of the Royal College of Physicians of Ireland, and was awarded the ESCMID fellowship.

In 2021 he was elected member of the Koninklijke Nederlandse Academi voor Wetenschappen.

Research Output (730)

Universal risk assessment upon hospital admission for screening of carriage with multidrug-resistant micro-organisms in a Dutch tertiary care centre

van Hout Denise, Bruijning-Verhagen Patricia C J, Blok Hetty, Troelstra Annet, Bonten Marc J M mrt 2021, In: The journal of Hospital Infection. 109 , p. 32-39 8 p.

Glycoproteoform Profiles of Individual Patients' Plasma Alpha-1-Antichymotrypsin are Unique and Extensively Remodeled Following a Septic Episode

Čaval Tomislav, Lin Yu-Hsien, Varkila Meri, Reiding Karli R, Bonten Marc J M, Cremer Olaf L, Franc Vojtech, Heck Albert J R 14 jan 2021, In: Frontiers in Immunology. 11

O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

Verboom D M, Varkila M R J, Morrow B, Davies T, Ibarra de Palacios P, Poolman J, Hermans P W M, Dudley E G, Roberts E, Cremer O L, Bonten M J M 2021, In: Vaccine. 39 , p. 1670-1674 5 p.

The leukocyte non-coding RNA landscape in critically ill patients with sepsis

Scicluna Brendon P, Uhel Fabrice, van Vught Lonneke A, Wiewel Maryse A, Hoogendijk Arie J, Baessman Ingelore, Franitza Marek, Nürnberg Peter, Horn Janneke, Cremer Olaf L, Bonten Marc J, Schultz Marcus J, van der Poll Tom, 11 dec 2020, In: eLife. 9 , p. 1-23 23 p.

Evolution of colistin resistance in the Klebsiella pneumoniae complex follows multiple evolutionary trajectories with variable effects on fitness and virulence characteristics

Janssen Axel B, Doorduijn Dennis J, Mills Grant, Rogers Malbert R C, Bonten Marc J M, Rooijakkers Suzan H M, Willems Rob J L, Bengoechea Jose A, van Schaik Willem 2 nov 2020, In: Antimicrobial Agents and Chemotherapy. 65 , p. 1-15

The burden of bacteremic and non-bacteremic Gram-negative infections:a prospective multicenter cohort study in a low-resistance country

Deelen J W Timotëus, Rottier Wouter C, van Werkhoven Cornelis H, Woudt Sjoukje H S, Buiting Anton G M, Dorigo-Zetsma J Wendelien, Kluytmans Jan A J W, van der Linden Paul D, Thijsen Steven F T, Vlaminckx Bart J M, Weersink Annemarie J L, Ammerlaan Heidi S M, Bonten Marc J M 5 okt 2020, In: The Journal of Infection. 81 , p. 895-901 7 p.

Anticoagulant interventions in hospitalized patients with COVID-19:A scoping review of randomized controlled trials and call for international collaboration

Tritschler Tobias, Mathieu Marie-Eve, Skeith Leslie, Rodger Marc, Middeldorp Saskia, Brighton Timothy, Sandset Per Morten, Kahn Susan R, Angus Derek C, Blondon Marc, Bonten Marc J, Cattaneo Marco, Cushman Mary, Derde Lennie P G, DeSancho Maria T, Diehl Jean-Luc, Goligher Ewan, Jilma Bernd, Jüni Peter, Lawler Patrick R, Marietta Marco, Marshall John C, McArthur Colin, Miranda Carlos Henrique, Mirault Tristan, Morici Nuccia, Perepu Usha, Schörgenhofer Christian, Sholzberg Michelle, Spyropoulos Alex C, Webb Steve A, Zarychanski Ryan, Zuily Stéphane, Le Gal Grégoire, 5 sep 2020, In: Journal of thrombosis and haemostasis : JTH. 18 , p. 2958-2967 10 p.

Clonal transmission of multidrug-resistant Acinetobacter baumannii harbouring blaOXA-24-like and blaOXA-23-like genes in a tertiary hospital in Albania

Tafaj Silva, Kostyanev Tomislav, Xavier Basil B, Fluit Ad C, Rodrigues Célia F, Lammens Christine, Osmalli Damiana, Raka Lul, Goossens Herman, Malhotra-Kumar Surbhi, Bonten Marc J M 2 sep 2020, In: Journal of global antimicrobial resistance. 23 , p. 79-81 3 p.

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19:The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Angus Derek C, Derde Lennie, Al-Beidh Farah, Annane Djillali, Arabi Yaseen, Beane Abigail, van Bentum-Puijk Wilma, Berry Lindsay, Bhimani Zahra, Bonten Marc, Bradbury Charlotte, Brunkhorst Frank, Buxton Meredith, Buzgau Adrian, Cheng Allen C, de Jong Menno, Detry Michelle, Estcourt Lise, Fitzgerald Mark, Goossens Herman, Green Cameron, Haniffa Rashan, Higgins Alisa M, Horvat Christopher, Hullegie Sebastiaan J, Kruger Peter, Lamontagne Francois, Lawler Patrick R, Linstrum Kelsey, Litton Edward, Lorenzi Elizabeth, Marshall John, McAuley Daniel, McGlothin Anna, McGuinness Shay, McVerry Bryan, Montgomery Stephanie, Mouncey Paul, Murthy Srinivas, Nichol Alistair, Parke Rachael, Parker Jane, Rowan Kathryn, Sanil Ashish, Santos Marlene, Saunders Christina, Seymour Christopher, Turner Anne, van de Veerdonk Frank, Venkatesh Balasubramanian, 2 sep 2020, In: JAMA - The Journal of The American Medical Association. 324 , p. 1317-1329 13 p.

Association of Staphylococcus aureus Colonization and Pneumonia in the Intensive Care Unit

Paling Fleur P, Hazard Derek, Bonten Marc J M, Goossens Herman, Jafri Hasan S, Malhotra-Kumar Surbhi, Sifakis Frangiscos, Weber Susanne, Kluytmans Jan A J W, 1 sep 2020, In: JAMA network open. 3 , p. 1-12

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet